Predicting binding affinity doesn’t work — or does it?

webinar

Tue, 16 Jun 2015, 19:00 CEST (Berlin)

Dr. Carsten Detering, BioSolveIT GmbH, St. Augustin, Germany

Predicting binding affinity doesn’t work — or does it?

Predicting binding affinity is still regarded as the holy grail. With SeeSAR, however, we are one step closer to accurately and reliably predict a protein-ligand’s binding affinity. What one often neglects is the accuracy of the data, and that, especially in brute force correlation analysis, we might compare apples with oranges.

SeeSAR will tell you where the problems are. So you can understand, without looking at any numbers, where you might have to optimize or where a crystal structure might not be credible. Because they are not, as Derek Lowe once put it, a “message from God”, but full of assumptions themselves. If we start to understand incorporate this in our work, we will see calculated binding affinity in a whole new (green) light.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on